With the proliferation of the electronic health record, automated "alerts" have proliferated. Alerts can remind providers about drug-drug interactions, necessary screening tests, or even notify them of possible diagnoses. Despite their ubiquity, the efficacy of alerts has rarely been measured in a systematic fashion. If alerting is not assessed appropriately, potentially ineffective alerts will proliferate, which can cause fatigue, whereby providers begin to ignore alerts that may be important.
The ELAIA projects seek to evaluate the efficacy of electronic alerts for Acute Kidney Injury by using randomized trial designs. Trials will examine the efficacy of AKI alerts by various mechanisms, the efficacy of AKI alerts in the setting of key kidney-toxic drugs, and the ability to target alerts using uplift modeling.
Postgraduate Associate, Yale University
Harold Feldman, MD, MSCE
George S. Pepper Professor of Public Health and Preventative Medicine, Yale University
Amit Garg, MD, PhD
Professor of Medicine (Nephrology), Western University, London, Ontario, Canada
Stephen Latham, JD, PhD
Director, Interdisciplinary Center for Bioethics, Yale University
Paul M. Palevsky, MD
Professor of Medicine, Renal-Electrolyte Division, University of Pittsburgh
- Oh J, Bia JR, Ubaid-Ullah M, Testani JM, Wilson FP: Provider acceptance of an automated electronic alert for acute kidney injury. Clin Kidney J. 2016 Aug; 2016 Jun 10. PMID: 27478598
- Wilson FP, Shashaty M, Testani J, Aqeel I, Borovskiy Y, Ellenberg SS, Feldman HI, Fernandez H, Gitelman Y, Lin J, Negoianu D, Parikh CR, Reese PP, Urbani R, Fuchs B: Automated, electronic alerts for acute kidney injury: a single-blind, parallel-group, randomised controlled trial. Lancet. 2015 May 16; 2015 Feb 26. PMID: 25726515
- Wilson FP, Reese PP, Shashaty MG, Ellenberg SS, Gitelman Y, Bansal AD, Urbani R, Feldman HI, Fuchs B: A trial of in-hospital, electronic alerts for acute kidney injury: design and rationale. Clin Trials. 2014 Oct; 2014 Jul 14. PMID: 25023200